Immunohistochemical staining of human breast cancer tissue with NFKB2 (phospho S870) polyclonal antibody (Cat# PAB29600) without blocking peptide (A) or preincubated with blocking peptide (B) under 1:50-1:100 dilution.
Immunofluorescent staining of methanol-fixed Hela cells using NFKB2 (phospho S870) polyclonal antibody (Cat# PAB29600) at 1:100-1:200 dilution.
NFKB has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NFKB is activated by a wide variety of stimuli such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth. For reviews, see Chen et al. (1999) [PubMed 9895331] and Baldwin (1996) [PubMed 8717528].[supplied by OMIM
OTTHUMP00000020371,OTTHUMP00000059136,nuclear factor of kappa light chain gene enhancer in B-cells 2,nuclear factor of kappa light polypeptide gene enhancer in B-cells 2